KYNB

Kyntra Bio, Inc.

Healthcare
Biotechnology
$32M market cap

Forecast run · Sep 14, 2026Upside rank 848 of 3,136

Model Signal

ForecastQ Daily Probabilities

48.1%

34.8%

15.8%

Analyst Consensus

Recommendation2.80/5 Hold

Last price$7.97

Price target$28.00

Implied move+251.3%

Analysts15

ForecastQ Portfolios

KYNB is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.